Mpm Bioventures Iii Parallel Fund, Lp - Net Worth and Insider Trading

Mpm Bioventures Iii Parallel Fund, Lp Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Mpm Bioventures Iii Parallel Fund, Lp owns 8 companies in total, including Radius Health Inc (RDUS) , Humanigen Inc (HGENQ) , and EPIRUS Biopharmaceuticals Inc (EPRSQ) among others .

Click here to see the complete history of Mpm Bioventures Iii Parallel Fund, Lp’s form 4 insider trades.

Insider Ownership Summary of Mpm Bioventures Iii Parallel Fund, Lp

Ticker	Comapny	Transaction Date	Type of Owner
RDUS	Radius Health Inc	2011-05-17	10 percent owner
HGENQ	Humanigen Inc	2012-08-11	10 percent owner
EPRSQ	EPIRUS Biopharmaceuticals Inc	2011-10-27	10 percent owner
		2010-12-14	other: Former 10% Owner
		2007-08-03	other: See explanation below
		2010-09-30	10 percent owner
		2009-11-05	10 percent owner
		2003-06-26	10 percent owner

Mpm Bioventures Iii Parallel Fund, Lp Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Mpm Bioventures Iii Parallel Fund, Lp Ownership Network

Ownership Network List of Mpm Bioventures Iii Parallel Fund, Lp

No Data

Ownership Network Relation of Mpm Bioventures Iii Parallel Fund, Lp

Mpm Bioventures Iii Parallel Fund, Lp Owned Company Details

What does Radius Health Inc do?

Who are the key executives at Radius Health Inc?

Mpm Bioventures Iii Parallel Fund, Lp is the 10 percent owner of Radius Health Inc. Other key executives at Radius Health Inc include director & CEO and President G. Kelly Martin , Senior Vice President Elizabeth Messersmith , and Vice President & Sales Danielle Holtschlag .

Radius Health Inc (RDUS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Radius Health Inc (RDUS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Radius Health Inc (RDUS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Radius Health Inc (RDUS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Radius Health Inc Insider Transactions

No Available Data

What does Humanigen Inc do?

Who are the key executives at Humanigen Inc?

Mpm Bioventures Iii Parallel Fund, Lp is the 10 percent owner of Humanigen Inc. Other key executives at Humanigen Inc include 10 percent owner Dale Chappell , Chief Medical Officer Adrian Kilcoyne , and Chief Commercial Officer Edward P. Jordan .

Humanigen Inc (HGENQ) Insider Trades Summary

Over the past 18 months, Mpm Bioventures Iii Parallel Fund, Lp made no insider transaction in Humanigen Inc (HGENQ). Other recent insider transactions involving Humanigen Inc (HGENQ) include a net sale of 386,350 shares made by Dale Chappell ,

In summary, during the past 3 months, insiders sold 0 shares of Humanigen Inc (HGENQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 386,350 shares of Humanigen Inc (HGENQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 386,350 shares.

Humanigen Inc (HGENQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Humanigen Inc Insider Transactions

No Available Data

What does EPIRUS Biopharmaceuticals Inc do?

Who are the key executives at EPIRUS Biopharmaceuticals Inc?

Mpm Bioventures Iii Parallel Fund, Lp is the 10 percent owner of EPIRUS Biopharmaceuticals Inc. Other key executives at EPIRUS Biopharmaceuticals Inc include Chief Business Officer Vincent Aurentz , Chief Financial Officer Thomas A. Shea , and director & Chief Executive Officer Amit Munshi .

EPIRUS Biopharmaceuticals Inc (EPRSQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of EPIRUS Biopharmaceuticals Inc (EPRSQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of EPIRUS Biopharmaceuticals Inc (EPRSQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

EPIRUS Biopharmaceuticals Inc (EPRSQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

EPIRUS Biopharmaceuticals Inc Insider Transactions

No Available Data

What does Reshape Lifesciences Inc do?

Who are the key executives at Reshape Lifesciences Inc?

Mpm Bioventures Iii Parallel Fund, Lp is the other: Former 10% Owner of Reshape Lifesciences Inc. Other key executives at Reshape Lifesciences Inc include Chief Financial Officer Thomas Stankovich , President and CEO Barton P. Bandy , and director & Chairman & President and CEO Dan W Gladney .

Reshape Lifesciences Inc (RSLS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Reshape Lifesciences Inc (RSLS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Reshape Lifesciences Inc (RSLS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Reshape Lifesciences Inc (RSLS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Reshape Lifesciences Inc Insider Transactions

No Available Data

What does Altimmune Inc do?

Who are the key executives at Altimmune Inc?

Mpm Bioventures Iii Parallel Fund, Lp is the other: See explanation below of Altimmune Inc. Other key executives at Altimmune Inc include Chief Financial Officer Richard I Eisenstadt , Chief Medical Officer Matthew Scott Harris , and Chief Business Officer Raymond M Jordt .

Altimmune Inc (ALT) Insider Trades Summary

Over the past 18 months, Mpm Bioventures Iii Parallel Fund, Lp made no insider transaction in Altimmune Inc (ALT). Other recent insider transactions involving Altimmune Inc (ALT) include a net sale of 15,711 shares made by David Drutz ,

In summary, during the past 3 months, insiders sold 16,011 shares of Altimmune Inc (ALT) in total and bought 0 shares, with a net sale of 16,011 shares. During the past 18 months, 16,011 shares of Altimmune Inc (ALT) were sold and 300 shares were bought by its insiders, resulting in a net sale of 15,711 shares.

Altimmune Inc (ALT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Altimmune Inc Insider Transactions

No Available Data

What does ARYx Therapeutics Inc do?

Who are the key executives at ARYx Therapeutics Inc?

Mpm Bioventures Iii Parallel Fund, Lp is the 10 percent owner of ARYx Therapeutics Inc. Other key executives at ARYx Therapeutics Inc include 10 percent owner Krishna Kittu Kolluri , 10 percent owner Growth Equity Opportunities Fund, Llc , and 10 percent owner Mark W Perry .

ARYx Therapeutics Inc (ARYX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of ARYx Therapeutics Inc (ARYX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of ARYx Therapeutics Inc (ARYX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

ARYx Therapeutics Inc (ARYX)'s detailed insider trading history can be found in Insider Trading Tracker table.

ARYx Therapeutics Inc Insider Transactions

No Available Data

What does Poniard Pharmaceuticals Inc do?

Who are the key executives at Poniard Pharmaceuticals Inc?

Mpm Bioventures Iii Parallel Fund, Lp is the 10 percent owner of Poniard Pharmaceuticals Inc. Other key executives at Poniard Pharmaceuticals Inc include President & CMO Michael S Perry , director & Chief Executive Officer Ron Martell , and director & 10 percent owner Simon Nicholas J Iii .

Poniard Pharmaceuticals Inc (PARD) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Poniard Pharmaceuticals Inc (PARD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Poniard Pharmaceuticals Inc (PARD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Poniard Pharmaceuticals Inc (PARD)'s detailed insider trading history can be found in Insider Trading Tracker table.

Poniard Pharmaceuticals Inc Insider Transactions

No Available Data

What does Rigel Pharmaceuticals Inc do?

Who are the key executives at Rigel Pharmaceuticals Inc?

Mpm Bioventures Iii Parallel Fund, Lp is the 10 percent owner of Rigel Pharmaceuticals Inc. Other key executives at Rigel Pharmaceuticals Inc include Sr VP of Bus Dev and Com Ops Raul R Rodriguez , EVP & Chief Commercial Officer David A Santos , and EVP & Chief Financial Officer Dean L Schorno .

Rigel Pharmaceuticals Inc (RIGL) Insider Trades Summary

Over the past 18 months, Mpm Bioventures Iii Parallel Fund, Lp made no insider transaction in Rigel Pharmaceuticals Inc (RIGL). Other recent insider transactions involving Rigel Pharmaceuticals Inc (RIGL) include a net sale of 52,894 shares made by Raul R Rodriguez , a net sale of 14,519 shares made by David A Santos , and a net sale of 12,628 shares made by Dean L Schorno .

In summary, during the past 3 months, insiders sold 0 shares of Rigel Pharmaceuticals Inc (RIGL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 8,004 shares of Rigel Pharmaceuticals Inc (RIGL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 8,004 shares.

Rigel Pharmaceuticals Inc (RIGL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Rigel Pharmaceuticals Inc Insider Transactions

No Available Data

Mpm Bioventures Iii Parallel Fund, Lp Mailing Address

Above is the net worth, insider trading, and ownership report for Mpm Bioventures Iii Parallel Fund, Lp. You might contact Mpm Bioventures Iii Parallel Fund, Lp via mailing address: The John Hancock Tower, 200 Clarendon Street, 54th Floor, Boston Ma 02116.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.